Research and Development of Neurological and Psychiatric Drugs Supported by National Science and Technology Major Project of “Major New Drugs R&D”

摘要/Abstract

摘要： National Science and Technology Major Project of "Major New Drugs R&D" have made great achievements during nearly 10 years since it was launched in 2008. In major drug research and development, a batch of innovative drugs for treatment of major diseases which seriously endanger the health of our people, such as cancer, cardiovascular disease, inflammatory disease, bacterial and virus bacterial infection diseases, etc., have been successfully developed. On the other hand, a number of common clinical drugs have been reformed technically and the qualities of them are improved significantly, aiming at the requirements of clinical medication. The research and development of new drugs of neuropsychiatric diseases are one of the important field supported by "Major New Drugs R&D" project. Up to now, more that 180 new drug projects of neuropsychiatric diseases in different research and development stages have been supported by the project, and some of them have made significant progresses and show potential and good prospects for development. For example, Morinda officinalis oligosaccharides, an antidepressant, has been approved and available to the public. 971, a new drug for treatment of Alzheimer's disease, has completed phase III clinical trials and obtained very good and encouraging results. Orcinoside, an antidepressant, is undergoing Phase II clinical trials. The research of sustained-release microsphere of antipsychotic drug, risperidone, has made significant progress.
The period of the 13th Five-Year Plan is the final five years and final stage for implementation of "Major New Drugs R&D" Project. With the economic and social development, the demands of protecting health and improving people's livelihood are even greater and stronger. Thus, it is of great significance to implement "Major New Drugs R&D" Project better and faster. During the 13th Five-Year Plan, the project fully implements the innovation-driven development strategy, and further focuses on its purpose, emphasizes the key points and accelerates implementation according to the principle of focus development. Further more, the project focuses on new drug research and development and the related key technology studies, and strengthens the construction of innovation capabilities. The main tasks have been arranged according to the “Three Importance” principle which means research and development of major new drugs, meeting important needs and solving important problems, so that to make the aims and tasks of the project more focused and clearer. Next, the development strategy study of the14th Five-Year Plan for "Major New Drugs R&D" project will be initiated. The research and development of neuropsychiatric drugs would still be a major field in the project. On one hand, "Major New Drugs R&D" project would further advance of technological innovation and research innovative drugs. Meanwhile, based on long-term development, the project would support and strengthen the related basic research of neuropsychiatric disease, translate and apply the results of basic research to provide rich knowledge for new drugs research and development. On the other hand, fully taking advantage of traditional Chinese medicine to discover and develop new neuropsychiatric drugs from traditional Chinese medicine is of great significance with a broad application perspective.

Abstract: National Science and Technology Major Project of "Major New Drugs R&D" have made great achievements during nearly 10 years since it was launched in 2008. In major drug research and development, a batch of innovative drugs for treatment of major diseases which seriously endanger the health of our people, such as cancer, cardiovascular disease, inflammatory disease, bacterial and virus bacterial infection diseases, etc., have been successfully developed. On the other hand, a number of common clinical drugs have been reformed technically and the qualities of them are improved significantly, aiming at the requirements of clinical medication. The research and development of new drugs of neuropsychiatric diseases are one of the important field supported by "Major New Drugs R&D" project. Up to now, more that 180 new drug projects of neuropsychiatric diseases in different research and development stages have been supported by the project, and some of them have made significant progresses and show potential and good prospects for development. For example, Morinda officinalis oligosaccharides, an antidepressant, has been approved and available to the public. 971, a new drug for treatment of Alzheimer's disease, has completed phase III clinical trials and obtained very good and encouraging results. Orcinoside, an antidepressant, is undergoing Phase II clinical trials. The research of sustained-release microsphere of antipsychotic drug, risperidone, has made significant progress.
The period of the 13th Five-Year Plan is the final five years and final stage for implementation of "Major New Drugs R&D" Project. With the economic and social development, the demands of protecting health and improving people's livelihood are even greater and stronger. Thus, it is of great significance to implement "Major New Drugs R&D" Project better and faster. During the 13th Five-Year Plan, the project fully implements the innovation-driven development strategy, and further focuses on its purpose, emphasizes the key points and accelerates implementation according to the principle of focus development. Further more, the project focuses on new drug research and development and the related key technology studies, and strengthens the construction of innovation capabilities. The main tasks have been arranged according to the “Three Importance” principle which means research and development of major new drugs, meeting important needs and solving important problems, so that to make the aims and tasks of the project more focused and clearer. Next, the development strategy study of the14th Five-Year Plan for "Major New Drugs R&D" project will be initiated. The research and development of neuropsychiatric drugs would still be a major field in the project. On one hand, "Major New Drugs R&D" project would further advance of technological innovation and research innovative drugs. Meanwhile, based on long-term development, the project would support and strengthen the related basic research of neuropsychiatric disease, translate and apply the results of basic research to provide rich knowledge for new drugs research and development. On the other hand, fully taking advantage of traditional Chinese medicine to discover and develop new neuropsychiatric drugs from traditional Chinese medicine is of great significance with a broad application perspective.

ZHANG Yong-xiang. Research and Development of Neurological and Psychiatric Drugs Supported by National Science and Technology Major Project of “Major New Drugs R&D”[J]. 神经药理学报, 2018, 8(4): 17-18.